Navigating the complexities of rare disease drug development
![](https://boydconsultants.com/wp-content/uploads/2024/02/Website-news-cover-image-size-82-1.png)
In this article, Dr Eric Hardter, Associate Director of Regulatory Affairs at Boyds, discusses the investigational phase of the rare disease drug development process with a focus on US regulatory requirements.